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Introduction: The development of factor VIII inhibitors is a serious complication of replacement therapy in patients
with congenital hemophilia A. Immune tolerance induction has been accepted as the only clinically proven
treatment allowing antigen-specific tolerance to factor VIII. However, some of its issues, such as patient selection,
timing, factor VIII dosing, use of immunosuppressive or immunomodulatory procedures, still remain the subject of
debate.
Case presentation: A case of a 3-year-old Caucasian boy with severe congenital hemophilia A, intron 22
inversion of the F8 gene and high-titer inhibitor, who underwent an immune tolerance induction according to
the modified Bonn regimen (high doses of plasma-derived factor VIII rich in von Willebrand factor and pulsed
intravenous immunoglobulin) is presented. The treatment lasted for 13 months and led to the eradication of
inhibitor.
Conclusion: Addition of intravenous immunoglobulin did not negatively affect the course of immune tolerance
induction and led to the rapid eradication of factor VIII inhibitor.
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The development of factor VIII (FVIII) inhibitors is a
serious complication of replacement therapy in patients
with congenital hemophilia A, affecting up to 35%, pre-
dominantly those with severe disease [1]. It leads to the
failure of previously efficient replacement therapy or
prophylaxis with FVIII and thus to an increased risk of
bleeding, joint impairment and reduced quality of life.
Immune tolerance induction (ITI) has been accepted as
the only clinically proven treatment allowing antigen-
specific tolerance to FVIII [2,3]. However, some of its
issues, such as patient selection, timing, FVIII dosing,
use of immunosuppressive or immunomodulatory* Correspondence: hema@jfmed.uniba.sk
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reproduction in any medium, provided the orprocedures, still remain unclear. Several modifications of
the first ITI treatment proposed in Bonn (Bonn regimen)
have been described, but none have been proved to be
superior [3-7].Case presentation
We present a successful use of the high-dose FVIII
regimen for ITI: plasma-derived FVIII rich in von
Willebrand factor (vWF) and pulsed intravenous
immunoglobulin (IVIG). The high-dose FVIII regimen
was used in a 3-year-old Caucasian boy with severe con-
genital hemophilia A (endogenous FVIII level below
0.01IU/mL), the intron 22 inversion of the F8 gene and
high-titer FVIII inhibitor. The patient was treated with
on-demand replacement therapy with a single human
plasma-derived FVIII concentrate rich in vWF (Fanhdi®,
Grifols, Barcelona, Spain) from the age of 2 months. TheLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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the availability of FVIII products at the start of the treat-
ment. The FVIII inhibitor in a high titer occurred after
2 years of treatment and 20 exposure days (initial inhibitor
titer (IT): 5.4BU/mL; Day −453, 453 days before the start of
ITI). In order to prevent further immunization, FVIII was
omitted from the treatment and on-demand recombinant
activated factor VII (rFVIIa; NovoSeven®, NovoNordisk®,
Bagsværd, Denmark) was used instead for maintaining
hemostasis. The activated prothrombin complex concen-
trate factor VIII inhibitor bypass activity (FEIBA [factor
eight inhibitor bypass activity]; Baxter International Inc.,
Deerfield, IL, USA) was not preferred due to the known
risk of anamnestic response and prolongation of time
period necessary for IT decrease. Within 14 months IT
spontaneously decreased to 0.8BU/mL and thus, at the age
of 3 years and 20 days, the first ITI could be started. The
previously described ITI regimen – a combination of high
doses of FVIII as in the original Bonn protocol (100IU/kg
intravenous (IV) twice a day; the same FVIII concentrate as
in the previous treatment) and pulsed IVIG (1g/kg IV on
Days 0, 1, 7, 15 and 21; Kiovig, Baxter AG, Wien, Austria)
– was used [5].
Invasive procedures as well as bleedings were managed
with on-demand rFVIIa (90μg/kg IV as a bolus, repeated
every 2 hours until the cessation of bleeding). The stable
IV access was secured via the central venous access
device (CVAD; PORT-A-CATH®, Smiths Medical, St.
Paul, MN, USA) placed in the subclavian vein. IT imme-
diately before the start of ITI (Day −3, 3 days before the
start of ITI) was 0.8BU/mL; its highest level was
10.0BU/mL. During ITI, the highest IT was observed in
the first month (72.0BU/mL), whereas from the
second month only low IT was found with a transient
increase during infections. After 12 months IT
decreased to 0.1BU/mL and the FVIII pharmacokinetics
normalized (recovery time 30 minutes after FVIII:
84.4%; plasma half-life: 6.5 hours; IV response to FVIII:
1.69IU/kg; normal FVIII clearance; testing performed
on Day 383 of ITI). Thus, ITI was considered success-
ful and terminated on Day 387 of ITI (Figure 1). No
adverse events directly associated with the administered
agents were observed during ITI.
Only one serious hemorrhage (intramuscular in the
left thigh; Day 21 of ITI) occurred; its cessation was
achieved solely with bypass therapy. However, ITI was
complicated with severe bacterial infections associated
with CVAD (three episodes of catheter-related sepsis;
Days 25, 188, and 216 of ITI).
The prophylactic re-treatment with the same plasma-
derived FVIII (Fanhdi® 1000IU IV thrice a week without
gradual tapering) was initiated after ITI termination.
During a 10-month follow-up, no clinical or laboratory
signs of FVIII inhibitor and no severe bleeding appeared.Discussion
Although current knowledge of ITI is based predomin-
antly on results of uncontrolled retrospective studies,
case reports and patient registries (International Im-
mune Tolerance Registry, German Registry, North
American Immune Tolerance Registry) with limited
directed comparison of different regimens, it is com-
monly accepted that the outcome of ITI is worse in
patients with IT more than 10BU/mL at ITI initiation,
historical IT more than 200BU/mL and peak IT on ITI
more than 250BU/mL [3,7]. Other negative factors –
age over 20 years at beginning of ITI, persistence of in-
hibitor for more than 5 years, use of FVIII concentrates
without vWF, presence of null mutations within F8
gene, African origin, and inflammatory challenges dur-
ing ITI – were suggested by particular analyses [7-13].
However, the available clinical data on those para-
meters are not consistent and sufficient for their gen-
eral acceptance. The recently finished International
Immune Tolerance Study, involving 115 good-risk
patients with severe congenital hemophilia A and high-
titer inhibitor on ITI, verified the inverse correlation of
historical IT and peak IT on ITI with the treatment
success, but failed to show a significant effect of infec-
tions on its outcome [14].
The positive effect of IVIG addition to ITI has been
reported since the introduction of the Malmö protocol
[3,15]. The rapid, although time-limited, improvement in
FVIII pharmacokinetics and decrease in IT, accompanied
by lower bleeding tendency, was attributed to IVIG [15].
However, these reports are anecdotal and limited almost
exclusively to case reports. Therefore, a recent inter-
national consensus recommendation does not approve
the standard use of IVIG or other immunomodulating
agents in first-line ITI [13].
In the presented case, the patient had a good prognos-
tic profile, with the low initial, historical, and anamnestic
IT and with only one known negative factor (intron 22
inversion). The treatment was well tolerated with rela-
tively rare bleedings. CVAD-related sepsis was regarded
as the most serious complication. The infections, al-
though recurrent and associated with the transient ele-
vation of IT, did not result in a marked prolongation of
ITI. The normalization of FVIII pharmacokinetics was
seen after 13 months, so the ITI duration was compar-
able with the mean durations reported in the analyses of
patient registries [3,7]. The use of IVIG could, similarly
to the observations of other authors, contribute to the
relatively low frequency of severe hemorrhages and the
normal ITI duration despite repeated inflammatory chal-
lenges [4,12].
The bleeding episodes in hemophilia patients with
high-titer inhibitor, both prior to and during ITI, are
managed with bypass agents: rFVIIa and activated
Figure 1 The time changes in initial inhibitor titer (IT) and factor VIII (FVIII) recovery before and during immune tolerance induction
(ITI). IT constantly decreased after the FVIII discontinuation; during ITI, after the initial increase (up to 72.0BU/mL) in the first month (anamnestic
response), a constant decrease in IT was seen with a transient low increase (up to 12.0BU/mL) during severe infection (catheter-related sepsis) in
the second month; FVIII recovery continuously improved from the fourth month of ITI. BU = Bethesda unit; FVIII = factor VIII; FVIII P = prophylaxis
with factor VIII; IT = inhibitor titer; ITI = immune tolerance induction; IU = international unit; rFVIIa = recombinant activated factor VII.
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are comparable in terms of efficacy and safety. However,
the ability of FEIBA to induce anamnestic response, and
thus prolong the persistence of inhibitor, is a possibledrawback for its use in ITI. Although the negative effect
of this phenomenon on ITI outcome is not clear, FEIBA
is nowadays not recommended for the first-line treat-
ment in patients planned for ITI [13]. In concordance
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presented case.
Conclusions
We report a successful use of ITI consisting of high-
dose plasma-derived FVIII rich in vWF and IVIG in a
hemophilia patient with high-titer FVIII inhibitor and
intron 22 inversion. The addition of IVIG did not alter
the course of ITI or the patient’s condition.
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